The Experts below are selected from a list of 280260 Experts worldwide ranked by ideXlab platform
Jeremy Chataway - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
CNS Drugs, 2018Co-Authors: Floriana De Angelis, Domenico Plantone, Jeremy ChatawayAbstract:Multiple Sclerosis is an immune-mediated inflammatory disease of the central nervous system characterised by demyelination, neuroaxonal loss and a heterogeneous clinical course. Multiple Sclerosis presents with different phenotypes, most commonly a relapsing–remitting course and, less frequently, a progressive accumulation of disability from disease onset (primary progressive Multiple Sclerosis). The majority of people with relapsing–remitting Multiple Sclerosis, after a variable time, switch to a stage characterised by gradual neurological worsening known as secondary progressive Multiple Sclerosis. We have a limited understanding of the mechanisms underlying Multiple Sclerosis, and it is believed that Multiple genetic, environmental and endogenous factors are elements driving inflammation and ultimately neurodegeneration. Axonal loss and grey matter damage have been regarded as amongst the leading causes of irreversible neurological disability in the progressive stages. There are over a dozen disease-modifying therapies currently licenced for relapsing–remitting Multiple Sclerosis, but none of these has provided evidence of effectiveness in secondary progressive Multiple Sclerosis. Recently, there has been some early modest success with siponimod in secondary progressive Multiple Sclerosis and ocrelizumab in primary progressive Multiple Sclerosis. Finding treatments to delay or prevent the courses of secondary progressive Multiple Sclerosis is an unmet and essential goal of the research in Multiple Sclerosis. In this review, we discuss new findings regarding drugs with immunomodulatory, neuroprotective or regenerative properties and possible treatment strategies for secondary progressive Multiple Sclerosis. We examine the field broadly to include trials where participants have progressive or relapsing phenotypes. We summarise the most relevant results from newer investigations from phase II and III randomised controlled trials over the past decade, with particular attention to the last 5 years.
Heather Wood - One of the best experts on this subject based on the ideXlab platform.
-
Multiple Sclerosis: Biomarkers and genetic variants reflect disease course in Multiple Sclerosis
Nature reviews. Neurology, 2016Co-Authors: Heather WoodAbstract:Multiple Sclerosis: Biomarkers and genetic variants reflect disease course in Multiple Sclerosis
-
Multiple Sclerosis: Could Helicobacter pylori provide protection against Multiple Sclerosis?
Nature reviews. Neurology, 2016Co-Authors: Heather WoodAbstract:Multiple Sclerosis: Could Helicobacter pylori provide protection against Multiple Sclerosis?
-
Multiple Sclerosis: Smoking in patients with Multiple Sclerosis—is it ever too late to quit?
Nature reviews. Neurology, 2015Co-Authors: Heather WoodAbstract:Multiple Sclerosis: Smoking in patients with Multiple Sclerosis—is it ever too late to quit?
-
Multiple Sclerosis: Cognitive training provides lasting benefits for patients with Multiple Sclerosis.
Nature reviews. Neurology, 2012Co-Authors: Heather WoodAbstract:Multiple Sclerosis: Cognitive training provides lasting benefits for patients with Multiple Sclerosis
Lauren B Krupp - One of the best experts on this subject based on the ideXlab platform.
-
Management of pediatric Multiple Sclerosis
Therapy, 2008Co-Authors: Lauren B KruppAbstract:An increasing number of children and adolescents with Multiple Sclerosis are being identified and treated with disease-modifying therapies. As more rapid diagnosis is made possible due to the heightened awareness of pediatric Multiple Sclerosis among the pediatric and neurological communities, and the availability of MRI, the number of pediatric Multiple Sclerosis patients requiring treatment will grow over time. This review draws on information from adult and pediatric neurology sources and summarizes current available data on the management of pediatric Multiple Sclerosis.
Katie Kingwell - One of the best experts on this subject based on the ideXlab platform.
-
Multiple Sclerosis: characterization of lesion evolution in relapsing-remitting and secondary progressive Multiple Sclerosis.
Nature reviews. Neurology, 2012Co-Authors: Katie KingwellAbstract:Multiple Sclerosis: Characterization of lesion evolution in relapsing–remitting and secondary progressive Multiple Sclerosis
Floriana De Angelis - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
CNS Drugs, 2018Co-Authors: Floriana De Angelis, Domenico Plantone, Jeremy ChatawayAbstract:Multiple Sclerosis is an immune-mediated inflammatory disease of the central nervous system characterised by demyelination, neuroaxonal loss and a heterogeneous clinical course. Multiple Sclerosis presents with different phenotypes, most commonly a relapsing–remitting course and, less frequently, a progressive accumulation of disability from disease onset (primary progressive Multiple Sclerosis). The majority of people with relapsing–remitting Multiple Sclerosis, after a variable time, switch to a stage characterised by gradual neurological worsening known as secondary progressive Multiple Sclerosis. We have a limited understanding of the mechanisms underlying Multiple Sclerosis, and it is believed that Multiple genetic, environmental and endogenous factors are elements driving inflammation and ultimately neurodegeneration. Axonal loss and grey matter damage have been regarded as amongst the leading causes of irreversible neurological disability in the progressive stages. There are over a dozen disease-modifying therapies currently licenced for relapsing–remitting Multiple Sclerosis, but none of these has provided evidence of effectiveness in secondary progressive Multiple Sclerosis. Recently, there has been some early modest success with siponimod in secondary progressive Multiple Sclerosis and ocrelizumab in primary progressive Multiple Sclerosis. Finding treatments to delay or prevent the courses of secondary progressive Multiple Sclerosis is an unmet and essential goal of the research in Multiple Sclerosis. In this review, we discuss new findings regarding drugs with immunomodulatory, neuroprotective or regenerative properties and possible treatment strategies for secondary progressive Multiple Sclerosis. We examine the field broadly to include trials where participants have progressive or relapsing phenotypes. We summarise the most relevant results from newer investigations from phase II and III randomised controlled trials over the past decade, with particular attention to the last 5 years.
